Trial Profile
MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation Alone in Patients With Chronic Lymphocytic Leukemia.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms MABTENANCE
- 06 Jan 2020 Status changed from active, no longer recruiting to completed.
- 08 Jan 2019 Planned End Date changed from 1 Feb 2018 to 1 Jul 2019.
- 16 Feb 2018 The study has been completed in Bulgarian (End Date:2017-11-28) according to European Clinical Trials Database.